GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celestra Inc (XKRX:352770) » Definitions » Capital Expenditure

Celestra (XKRX:352770) Capital Expenditure : ₩-25,793.69 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Celestra Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Celestra's cash flow for capital expenditures for the three months ended in Dec. 2024 was ₩-169 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-25,793.69 Mil.

Celestra Capital Expenditure Historical Data

The historical data trend for Celestra's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celestra Capital Expenditure Chart

Celestra Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial -4,650.71 -10,276.35 -12,940.48 -1,927.10 -25,793.69

Celestra Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,271.93 -49.52 -11,954.20 -13,620.72 -169.25

Celestra Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-25,793.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celestra Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celestra Inc (XKRX:352770) » Definitions » Capital Expenditure
Comparable Companies
XKRX:341170 XKRX:066830 XKRX:244460 XKRX:188260 XKRX:266470 XKRX:251280 XKRX:299480 XKRX:179530 XKRX:322970 XKRX:065650 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Building 110, UNIST, 50, Suite 301-3, UNIST-gil, Eonyang-eup, Ulju-gun, Ulsan, KOR, 44919
Website
http://www.clinomics.com
Celestra Inc is a biotechnology company. The company provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology. It offers a genome-based, early cancer diagnostic service through technology for multi-omics analysis and simultaneous detection of CTC and cfDNA in the blood based.

Celestra Headlines

No Headlines